Arovella Therapeutics Ltd has released a press release.
Arovella to close its Perth OroMist R&D Facility
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- Preclinical trial of ALA iNKT therapy and IMU onCARlytics
- Preliminary Final Report
- Quarterly Appendix 4C and Activities Report
- Sumatriptan Update
- ZolpiMist Launch Australia
Later from Arovella Therapeutics
- Europe Patent granted for iNKT Cell Therapy Platform
- R&D Tax Incentive refund received
- Arovella completes $1.65M placement
- ALA-101 confers survival benefit in leukemia model
- Response to ASX Aware Query
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics